Comparison · NCT04467840-d945ca70
Opaganib vs Placebo: Number of Participants With Low Oxygen Flow Via Nasal Cannula
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Opaganib vs Placebo: Number of Participants With Low Oxygen Flow Via Nasal Cannula. Trial comparisons, record NCT04467840-d945ca70. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04467840-d945ca70
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.735 | 0.674 | 0.788 | wilson | |
| Risk in group 2 | 0.717 | 0.656 | 0.771 | wilson | |
| Risk difference, group 1 minus group 2 | 0.018 | -0.0631 | 0.0988 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.917 | 1.15 | log | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.728 | 1.65 | log | |
| Number needed to treat, for one more participant with the outcome on Opaganib than on Placebo | 55.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Opaganib | Opaganib administered orally in 2 x 250 mg capsules (500 mg) every 12 hours every day for 14 days (Day 1 to Day 14) in addition to standard of care. When required this may be made into a suspension form and may be administered by nasogastric tube. | 169 | 230 | OG000 |
| Group 2 | Placebo | Matching placebo administered orally in 2 x 250 mg capsules (500 mg) every 12 hours every day for 14 days (Day 1 to Day 14) in addition to standard of care. Where required this may be made into a suspension form and may be administered by nasogastric tube. | 167 | 233 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Low Oxygen Flow Via Nasal Cannula
- Description
To compare the time to low oxygen flow via nasal cannula e.g. from high oxygen flow via nasal cannula or CPAP, if high oxygen flow is not an available option between subjects taking opaganib and those on placebo.
- Time frame
- 14 days maintained up to 42 days
- Population
- mITT. In this analysis, subjects who required low-flow supplemental oxygen at Day 1 (baseline) were considered success events, and the time to event of interest for these subjects was defined as 0.
Source ClinicalTrials.gov
Trial
- Title
- Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
- NCT number
- NCT04467840
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19, Lung Infection
- Interventions
- Opaganib, Placebo
- Lead sponsor
- RedHill Biopharma Limited
- Results first posted
- 2023-10-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04467840?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04467840-d945ca70